Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Wuhan
Clinical trial register · China

Clinical Trials in Wuhan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology169 Tongji Hospital139 Huazhong University of Science and Technology41 Novartis Pharmaceuticals33 Zhongnan Hospital30
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Wuhan

1343 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Efficacy and Safety of Calculus Bovis Sativus in Adults With MAFLD
NCT07085962Metabolic Dysfunction-associated Fatty Liver Disease
DrugCalculus bovis sativus
Huazhong University of Science and Technology
Not applicable
40
Wuhan
2025-08-01
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
400
Wuhan
2025-08
Not yet open
CEH-EUS for Differentiating GISTs and Leiomyomas: A Multicenter Prospective Self-Controlled Study
NCT07106411Submucosal Tumor, Gastrointestinal Stromal Tumor (GIST), Leiomyoma
Huazhong University of Science and Technology
Observational
288
Wuhan
2025-08
Recruiting
Tongji Hospital
Phase 4
1,058
Wuhan
2025-07-31
Not yet open
A Clinical Study Evaluating the Dermal Safety of Soluble Denosumab Microneedle Patches
NCT07085520Osteoarthritis, Osteoarthritis (OA) of the Knee, Osteoporosis, Osteoporosis (Senile)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1
12
Wuhan
2025-07-31
Recruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1/2
97
Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan, Changsha
2025-07-30
Recruiting
Eli Lilly and Company
Phase 1/2
68
Guangzhou, Jinan, Tianjin, Wuhan
2025-07-30
Recruiting
Huazhong University of Science and Technology
Phase 4
170
Wuhan
2025-07-30
Not yet open
Tongji Hospital
Phase 2
300
Wuhan
2025-07-30
Recruiting
Celgene
Phase 3
400
Beijing, Fuzhou Fujian, Guangzhou, Harbin, Wuhan, Changsha, Hohhot, Suzhou
2025-07-28
Recruiting
A Study of LY4175408 in Participants With Advanced Cancer
NCT07046923Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis
DrugsCisplatin·Carboplatin·Pembrolizumab
Eli Lilly and Company
Phase 1
240
Chengdu, Shanghai, Wuhan
2025-07-28
Recruiting
Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis
NCT07078136Submucosal Tumor, Gastrointestinal Stromal Tumor (GIST), Leiomyoma, Schwannoma
Huazhong University of Science and Technology
Observational
130
Wuhan
2025-07-28
Recruiting
Shu Peng
Observational
1,500
Wuhan
2025-07-26
Recruiting
Renmin Hospital of Wuhan University
Not applicable
472
Wuhan
2025-07-26
Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
DrugMRG007
ArriVent BioPharma, Inc.
Phase 1
572
Beijing, Chongqing, Zhejiang, Heilongjiang, Zhengzhou, Wuhan, Changsha, Shandong
2025-07-25
Recruiting
Natural History Study of Inherited Retinal Diseases
NCT07085533Retinal Dystrophies, Color Vision Defects, Vision Disorders, Macular Degeneration
Augelux Therapeutics
Observational
200
Wuhan
2025-07-20
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
59
Wuhan
2025-07-19
Recruiting
BeOne Medicines
Phase 1
58
Beijing, Chongqing, Guangzhou, Wuhan, Changsha, Qingdao, Chengdu, Hangzhou
2025-07-19
Active, closed
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033Primary Myelofibrosis, Myeloproliferative Neoplasm
DrugBesremi
PharmaEssentia
Phase 3
160
Beijing, Chongqing, Guangdong, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing
2025-07-18
Recruiting
DualityBio Inc.
Phase 2
750
Beijing, Dongguan, Henan, Xinxiang, Hubei, Wuhan, Changsha, Xuzhou
2025-07-18
Recruiting
Akeso
Phase 2
100
Wuhan
2025-07-18
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
216
Beijing, Dongguan, Guangdong, Guangzhou, Anyang, Zhengzhou, Wuhan, Changsha
2025-07-15
Recruiting
Daishi Tian
Early Phase 1
6
Wuhan
2025-07-15
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1
12
Wuhan
2025-07-11
Recruiting
Huaqiu Zhang
Not applicable
60
Wuhan
2025-07-10
Not yet open
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
33
Wuhan
2025-07-10
Recruiting
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2
86
Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Shenyang, Hangzhou
2025-07-10
Recruiting
MITRIS China Post Market Clinical Follow-up (PMCF) Study
NCT07059793Mitral Valve Replacement
Edwards Lifesciences
Observational
250
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Nanjing, Xi'an, Jinan
2025-07-08
Recruiting
Interventions for Silent Brain Infarction and Perioperative Neurocognitive Disorders in Cardiovascular Surgery
NCT07048002Silent Brain Infarction, Neurocognitive Disorders, Cardiac Surgery, Neuroprotective
Chinese Academy of Medical Sciences, Fuwai Hospital
Not applicable
912
Beijing, Wuhan
2025-07-06
Recruiting
Tongji Hospital
Observational
100
Wuhan
2025-07-02
Recruiting
Tongji Hospital
Observational
200
Wuhan
2025-07-01
Recruiting
Novartis Pharmaceuticals
Phase 3
940
Fuzhou, Guangzhou, Wuhan, Nanjing, Shenyang, Chengdu, Hangzhou, Beijing
2025-07-01
Not yet open
Patient Journey in Advanced Gynecologic Cancers
NCT07015593Genital Neoplasms, Female, Uterine Cervical Neoplasms, Endometrial Carcinoma
Tongji Hospital
Observational
780
Hefei, Guangzhou, Wuhan, Chongqing
2025-07-01
Not yet open
AI-guided TIPS Procedure
NCT06837974Portal Hypertension Related to Cirrhosis
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not applicable
180
Wuhan
2025-07-01
Recruiting
Tongji Hospital
Not applicable
32
Wuhan
2025-07-01
Recruiting
Donghua Zhang
Not applicable
40
Wuhan
2025-07-01
Not yet open
Clinical Application of PET Imaging Targeting Nectin-4 in Malignant Tumors
NCT06994078Urothelial Carcinoma, Breast Cancer, Lung Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not applicable
56
Wuhan
2025-07-01
Not yet open
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1
12
Wuhan
2025-07-01
Recruiting
Rectal NSAIDs With/Without PD Stent for PEP Prevention
NCT07117318Post-ERCP Acute Pancreatitis, Non-steroid Anti-inflammatory Drugs, Pancreatic Duct Stent Placement
DrugNSAIDs
Air Force Military Medical University, China
Not applicable
1,278
Beijing, Chongqing, Xiamen, Harbin, Kaifeng, Wuhan, Changsha, Xi'an
2025-07-01
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
350
Wuhan
2025-07
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
400
Wuhan
2025-07
Not yet open
Surgery for Relapsed Ovarian Cancer in Precision
NCT06602063Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
DrugLenvatinib
Shanghai Gynecologic Oncology Group
Phase 1/2
33
Shanghai, Wuhan
2025-07
Recruiting
Cohort Study of Intrauterine Diseases
NCT07048327Endometrial Cancer, Endometrial Hyperplasia, Endometrial Polyps
Wenwen Wang
Observational
2,000
Wuhan
2025-07
Not yet open
22G-Adapt vs 22G-Franseen Needle Biopsy in EUS-Guided Tissue Acquisition of Solid Lesions
NCT07012694Pancreatic Neoplasms, Mediastinal Neoplasms, Abdominal Neoplasm, Excluding Pancreas Neoplasm
Huazhong University of Science and Technology
Not applicable
576
Wuhan
2025-07
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
40
Wuhan
2025-06-28
Recruiting
Randomised Controlled Trial of Artificial Intelligence-assisted Health Education
NCT07305337Leukaemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Lymphoma
Zhongnan Hospital
Not applicable
196
Wuhan
2025-06-28
Active, closed
Incyte Corporation
Phase 1/2
32
Beijing, Chengdu, Chongoing, Guangzhou, Hangzhou, Shanghai, Tianjin, Wuhan
2025-06-25
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1
28
Wuhan
2025-06-23
Recruiting
A Study in Children With Achondroplasia
NCT07301463Achondroplasia
Abbisko Therapeutics Co, Ltd
Observational
260
Beijing, Guangzhou, Zhengzhou, Wuhan, Shanghai, Chengdu, Hangzhou
2025-06-20
Recruiting
Jun Jia
Phase 2
30
Wuhan
2025-06-19
Active, closed
AbbVie
Phase 3
573
Hefei, Beijing, Chongqing, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha
2025-06-17
Recruiting
Bristol-Myers Squibb
Phase 3
274
Beijing, Wuhan, Changsha, Jining Shi, Tianjin
2025-06-13
Recruiting
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
NCT06933472Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
Alebund Pharmaceuticals
Phase 3
264
Beijing, Xiamen, Zhengzhou, Wuhan, Changsha, Nanjing, Nantong, Wuxi
2025-06-13
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Early Phase 1
10
Wuhan
2025-06-12
Recruiting
Zhuhai Fapon Biopharma Co., Ltd.
Phase 1
108
Guangzhou, Wuhan, Nanchang, Taiyuan, Hangzhou
2025-06-12
Recruiting
AI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)
NCT07062380Hepatecellular Carcinoma, Hepatectomy
Tongji Hospital
Observational
353
Wuhan
2025-06-10
Recruiting
Novartis Pharmaceuticals
Observational
80
Hefei, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nantong, Nanchang, Changchun
2025-06-10
Recruiting
Celgene
Phase 2
120
Hefei, Beijing, Wuhan, Nanjing, Shanghai Shi, Hangzhou
2025-06-09
Recruiting
Ausper Biopharma Co., Ltd.
Phase 2
200
Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Zunyi, Wuhan, Changchun
2025-06-08
Active, closed
Stoke Therapeutics, Inc
Phase 3
170
Beijing, Guangzhou, Wuhan
2025-06-04
Recruiting
Protein A Immunoadsorption in Dilated Cardiomyopathy (RPIA-DCM)
NCT06922851Dilated Cardiomyopathy (DCM)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not applicable
60
Wuhan
2025-06-04
Recruiting
Stem Cell Therapy for Intracerebral Hemorrhage
NCT06862388Intracerebral Hemorrhage, Mesenchymal Stem Cell
Tang Zhouping
Phase 1/2
39
Wuhan
2025-06-02
Recruiting
Indomethacin vs Diclofenac for Preventing PEP
NCT07071441ERCP, Pancreatitis, Non-steroidal Anti-inflammatory (NSAID), Indomethacin
DrugsIndomethacin·Diclofenac
Air Force Military Medical University, China
Not applicable
4,050
Beijing, Chongqing, Xiamen, Harbin, Kaifeng, Wuhan, Changsha, Jilin City
2025-06-01
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not applicable
66
Wuhan
2025-06-01
Not yet open
Tongji Hospital
Phase 1/2
90
Wuhan
2025-06-01
Recruiting
Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease
NCT07267117Heart Valve Disease, Mitral Valve (MV) Regurgitation, Mitral Valve Disease, Mitral Valve Stenosis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
10,000
Fuzhou, Wuhan, Changsha, Shenyang, Xi'an, Qingdao, Chengdu, Ürümqi
2025-06-01
Not yet open
Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis
NCT06961188Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene Negativity, Untreated With Systemic Therapy
DrugNano-crystalline Megestrol Acetate
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3
174
Wuhan
2025-06-01
Not yet open
Tongji Hospital
Phase 3
300
Wuhan
2025-06-01
Not yet open
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1
19
Wuhan
2025-06
Not yet open
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Early Phase 1
24
Wuhan
2025-06
Not yet open
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Early Phase 1
24
Wuhan
2025-06
Not yet open
Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
NCT07010588Hepatocellular Carcinoma (HCC), Magnetic Resonance Imaging (MRI), Randomized Controlled Trial
Peking University People's Hospital
Not applicable
1,389
Beijing, Chongqing, Handan, Harbin, Wuhan, Changchun, Jinan, Qingdao
2025-06
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Early Phase 1
24
Wuhan
2025-05-30
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Early Phase 1
24
Wuhan
2025-05-30
Recruiting
Tongji Hospital
Phase 3
424
Wuhan
2025-05-27
Recruiting
GeneCradle Inc
Phase 3
50
Beijing, Shanghai, Shenzhen, Suzhou, Wuhan
2025-05-27
Recruiting
Huaqiu Zhang
Phase 1
9
Wuhan
2025-05-26
Active, closed
Amgen
Phase 4
102
Beijing, Guangzhou, Shenzhen, Luoyang, Wuhan, Changzhou, Huaian, Nantong
2025-05-24
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 1
30
Hefei, Beijing, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2025-05-23
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
500
Hefei, Fuzhou, Guangzhou, Harbin, Zhenngzhou, Wuhan, Xining, Shanghai
2025-05-22
Not yet open
Tao Zhang
Phase 2
42
Wuhan
2025-05-20
Recruiting
Novartis Pharmaceuticals
Phase 3
348
Guangzhou, Shantou, Shenzhen, Liuzhou, Wuhan, Changchun, Shenyang, Binzhou
2025-05-19
Recruiting
Goal Commitment and Proactive Health Behavior in Chronic Disease Patients
NCT07552571Hypertension, Diabetes Mellitus, Dyslipidemia
Xiong Juyang
Not applicable
600
Wuhan
2025-05-15
Recruiting
Tongji Hospital
Early Phase 1
84
Wuhan
2025-05-15
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,440
Beijing, Chongqing, Fuzhou, Guangzhou, Zhuhai, Nanning, Zhengzhou, Wuhan
2025-05-13
Active, closed
Hoffmann-La Roche
Phase 1
20
Guangzhou, Tianjin, Nanchang, Wenzhou, Wuhan
2025-05-13
Recruiting
Sun Yat-Sen University Cancer Center
Phase 3
580
Fuzhou, Dongguan, Foshan, Guangzhou, Zhongshan, Nanning, Guiyang, Wuhan
2025-05-04
By invitation
Huazhong University of Science and Technology
Not applicable
700
Wuhan
2025-05-03
Not yet open
Wuhan University
Observational
70
Wuhan
2025-05-01
Recruiting
AstraZeneca
Phase 1
72
Beijing, Shanghai, Wuhan, Zhengzhou
2025-05-01
Recruiting
Wuhan Children's Hospital
Observational
100
Wuhan
2025-05-01
Recruiting
Hoffmann-La Roche
Phase 1
405
Guangzhou, Shanghai, Wuhan
2025-04-30
Active, closed
Study for AZD4360 in Participants With Advanced Solid Tumours
NCT06921928Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
AstraZeneca
Phase 1/2
31
Beijing, Chengdu, Shanghai, Wuhan
2025-04-29
Recruiting
Xiamen Amoytop Biotech Co., Ltd.
Phase 3
300
Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Zhengzhou, Wuhan
2025-04-28
Recruiting
Chongqing Precision Biotech Co., Ltd
Phase 1
60
Wuhan
2025-04-28
Recruiting
Changchun Tuohua Pharmaceutical Co., Ltd.
Phase 1/2
36
Wuhan
2025-04-25
Recruiting
Liu Huang
Phase 1/2
42
Wuhan
2025-04-25
Recruiting
Tongji Hospital
Observational
5,000
Enshi, Huanggang, Huangshi, Jingzhou, Shiyan, Suizhou, Wuhan, Xiangyang
2025-04-22
Recruiting
Cullgen (Shanghai),Inc
Phase 1
45
Nanchang, Tianjin, Wuhan
2025-04-17
Not yet open
(Withdrawal) AI-Based Low-Dose 3D-DSA Reconstruction
NCT06769867Cerebrovascular Disease
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not applicable
134
Wuhan
2025-04-15
Recruiting
Electrical Impedance Tomography-Based Prognostic Model for ARDS
NCT06967207Acute Respiratory Distress Syndrome (ARDS), Ventilator-induced Lung Injury
XiaoJing Zou,MD
Observational
625
Guangzhou, Wuhan, Shanghai
2025-04-15
Active, closed
Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
NCT06900543Unresectable Hepatocellular Carcinoma
DrugSIRT
Chengdu New Radiomedicine Technology Co. LTD.
Phase 3
108
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Nanjing, Shenyang, Xi’an, Chengdu
2025-04-15
Recruiting
Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases
NCT07092202Leptomeningeal Metastasis, NSCLC, Intrathecal Chemotherapy, Tyrosine Kinase Inhibitor
DrugsFurmonertinib·Pemetrexed
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 4
40
Wuhan
2025-04-15
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
72
Beijing, Chongqing, Harbin, Zhengzhou, Wuhan, Nanjing, Nanchang, Shenyang
2025-04-11
Active, closed
Arrowhead Pharmaceuticals
Phase 3
710
Bengbu, Beijing, Guangzhou, Liuzhou, Xingtai, Luoyang, Changsha, Wuhan
2025-04-09
Recruiting
Huazhong University of Science and Technology
Not applicable
2,500
Nanning, Tangshan, Shiyan, Wuhan, Chengdu
2025-04-08
Recruiting
Beijing Anzhen Hospital
Not applicable
146
Hefei, Beijing, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2025-04-08
Recruiting
Tongji Hospital
Not applicable
6
Wuhan
2025-04-05
Recruiting
Shanghai Institute Of Biological Products
Phase 1/2
645
Wuhan
2025-04-04
Recruiting
Peking University First Hospital
Not applicable
1,066
Beijing, Nanning, Wuhan
2025-04-02
Recruiting
Shanghai Henlius Biotech
Phase 2
70
Fuzhou, Dongguan, Guangzhou, Shenzhen, Nanning, Guiyang, Wuhan, Changsha
2025-04-02
Recruiting
Liling Zhang
Phase 2
40
Wuhan
2025-04-01
Not yet open
Granzyme B-targeted PET Imaging Monitoring Tumor Responses to Immunotherapy
NCT06916442PET/CT, Solid Tumors, Adult, Solid Tumors, Advanced Solid Tumors
Zhongnan Hospital
Observational
200
Wuhan
2025-04-01
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not applicable
100
Wuhan
2025-04-01
Recruiting
Maternal and Child Health Hospital of Hubei Province
Not applicable
150
Wuhan
2025-04-01
Recruiting
Sir Run Run Shaw Hospital
Phase 2
70
Guangzhou, Zhengzhou, Wuhan, Changsha, Hangzhou, Wenzhou
2025-04-01
Not yet open
Tongji Hospital
Phase 1/2
45
Wuhan
2025-04-01
Recruiting
Tongji Hospital
Observational
500
Wuhan
2025-04-01
Not yet open
Wuhan University
Observational
70
Wuhan
2025-04-01
Not yet open
Zhiyong Huang
Phase 1/2
60
Wuhan
2025-04-01
By invitation
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT06859099Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
300
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Wuhan
2025-04-01
Not yet open
Yunhe Pharmaceutical (Tianjin) Co., Ltd
Phase 3
240
Beijing, Cangzhou, Wuhan, Yichang, Changsha, Nanjing, Suzhou, Taizhou
2025-04
Not yet open
Yunhe Pharmaceutical (Tianjin) Co., Ltd
Phase 3
110
Beijing, Cangzhou, Wuhan, Yichang, Changsha, Nanjing, Suzhou, Taizhou
2025-04
Recruiting
Gritgen Therapeutics Co., Ltd.
Phase 3
50
Hefei, Beijing, Lanzhou, Guangzhou, Tangshan, Zhengzhou, Wuhan, Changsha
2025-03-31
Recruiting
Zhongnan Hospital
Phase 1
18
Wuhan
2025-03-30
Recruiting
Tongji Hospital
Phase 1
69
Wuhan
2025-03-28
Recruiting
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
NCT07152041Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic
DrugsOlverembatinib·Blinatumomab·Daunorubicin·Cytarabine
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
150
Hefei, Chongqing, Fuzhou, Guangzhou, Guiyang, Wuhan, Changsha, Nanjin
2025-03-28
Recruiting
Chongqing Precision Biotech Co., Ltd
Phase 1
15
Wuhan
2025-03-27
Recruiting
Manual Acupuncture (MA) for Asymptomatic Hyperuricemia (HUA)
NCT06824376Asymptomatic Hyperuricemia
Shenghao Tu
Not applicable
260
Wuhan
2025-03-25
Recruiting
Intraoperative Paravertebral Block and Postoperative Complications
NCT07211529Video-assisted Thoracoscopic Surgery (VATS), Lung Cancer (Diagnosis), Pulmonary Infections, Respiratory Failure Without Hypercapnia
Tongji Hospital
Not applicable
500
Wuhan
2025-03-25
Recruiting
Bayer
Phase 1/2
450
Beijing, Wuhan, Nanjing, Hangzhou
2025-03-21
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
100
Wuhan
2025-03-20
Recruiting
Effect of Adding Electroacupuncture to Anti-cancer Therapy-induced Peripheral Neuropathy
NCT06858709Chemotherapy-induced Peripheral Neuropathy (CIPN), Cancer
Zhongnan Hospital
Not applicable
150
Wuhan
2025-03-20
Active, closed
fMRI Study on Cerebral Localization and Network Mechanisms of rTMS in Chronic Ankle Instability Treatment
NCT06971705Chronic Ankle Instability, CAI, Functional Magnetic Resonance Imaging (fMRI)
Wuhan University
Not applicable
40
Wuhan
2025-03-20
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2
150
Wuhan
2025-03-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Bengbu, Chongqing, Xiamen, Guangzhou, Nanning, Zhengzhou, Wuhan, Xiangyang
2025-03-16
Active, closed
Hoffmann-La Roche
Phase 4
274
Beijing, Chengdu, Guangzhou, Shanghai, Wuhan
2025-03-14
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
300
Wuhan, Jinan
2025-03-13
Recruiting
The Dental Hospital of Zhejiang University School of Medicine
Not applicable
40
Wuhan, Hangzhou, Shanghai
2025-03-12
Recruiting
Newly-diagnosed Pediatric T-cell ALL Protocol
NCT06855810Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
DrugsAsparaginase·Homoharringtonine·Dasatinib·Daunorubicin
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3
610
Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Wuhan, Changsha
2025-03-11
Active, closed
Takeda
Phase 3
601
Bengbu, Beijing, Xiamen, Guangzhou, Shenzhen, Luoyang, Wuhan, Zhuzhou
2025-03-10
Active, closed
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
NCT06744647Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
DrugALXN2030
Alexion Pharmaceuticals, Inc.
Phase 2
47
Changsha, Guangzhou, Nanning, Shanghai, Wuhan, Xi'an
2025-03-07
Recruiting
AbbVie
Phase 1/2
252
Beijing, Fuzhou, Liuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang
2025-03-06
Recruiting
BeOne Medicines
Phase 3
300
Beijing, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Xuzhou
2025-03-05
Recruiting
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
NCT06882057Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)
DrugsAsparaginase·Blinatumomab·Daunorubicin·Cytarabine
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3
3,000
Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Wuhan, Changsha
2025-03-03
Not yet open
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not applicable
400
Wuhan
2025-03-01
Recruiting
Mechanisms And Prognosis of Stroke-Heart Syndrome
NCT06954103Stroke, Myocardial Injury, Heart Failure, Acute Coronary Syndromes
Chensheng Pan
Observational
658
Wuhan
2025-03-01
Recruiting
Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy
NCT07088354Esophageal Squamous Cell Carcinoma, Neoadjuvant Immunochemotherapy, Pathological Complete Response, Deep Learning
Tongji Hospital
Observational
300
Wuhan
2025-03-01
Recruiting
Children's Hospital of Soochow University
Not applicable
90
Wuhan, Suzhou, Changchun
2025-03
Recruiting
Bayer
Phase 1
148
Xuhui, Fujian, Wuhan
2025-02-28
Active, closed
A Phase 2 in Adult Subjects With Hereditary Angioedema
NCT06846398Hereditary Angioedema (HAE)
DrugBW-20805
Shanghai Argo Biopharmaceutical Co., Ltd.
Phase 2
25
Beijing, Lanzhou, Wuhan, Yantai, Chengdu, Kunming
2025-02-28
Recruiting
Tongji Hospital
Not applicable
20
Wuhan
2025-02-28
Recruiting
Novartis Pharmaceuticals
Phase 2/3
443
Fuzhou, Wuhan, Nanjing, Shenyang, Xian, Chengdu, Beijing, Guangzhou
2025-02-27
Recruiting
Takeda
Phase 3
171
Beijing, Guangzhou, Nanning, Shijiazhuang, Wuhan, Zhengzhou, Suzhou, Nanchang
2025-02-27
Recruiting
UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia
NCT06245746Acute Myeloid Leukemia, Neutropenia, Anemia, Thrombocytopenia
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1
9
Wuhan
2025-02-26
Recruiting
Bristol-Myers Squibb
Phase 3
530
Beijing, Chongqing, Fuzhou, Xiamen, Shantou, Harbin, Wuhan, Changsha
2025-02-25
Recruiting
Zhen Li
Observational
500
Wuhan
2025-02-25
Recruiting
Beijing Tuohua Weiye Biotechnology Co., Ltd.
Phase 1/2
76
Wuhan
2025-02-25
Recruiting
Maternal and Child Health Hospital of Hubei Province
Not applicable
300
Wuhan
2025-02-25
Recruiting
Huazhong University of Science and Technology
Not applicable
500
Zhanjiang, Wuhan
2025-02-24
Recruiting
Maternal and Child Health Hospital of Hubei Province
Not applicable
236
Wuhan
2025-02-22
Recruiting
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
NCT06839105Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor
DrugsAWT020·Taxol·Pemetrexed·Capecitabine
Shanghai Junshi Bioscience Co., Ltd.
Phase 1
214
Fuzhou, Guangzhou, Harbin, Luoyang, Wuhan, Changsha, Nanchang, Changchun
2025-02-21
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
246
Guangzhou, Guiyang, Wuhan, Yichang, Changsha, Yongzhou, Shanghai
2025-02-21
Active, closed
Gilead Sciences
Phase 2
39
Chengdu, Hangzhou, Nanning, Shanghai, Wuhan
2025-02-18
Recruiting
Shaogang Wang
Phase 3
180
Wuhan, Xiangyang
2025-02-17
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
25
Wuhan, Xiangyang
2025-02-17
Recruiting
Akeso
Phase 2
150
Wuhan
2025-02-17
Not yet open
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Early Phase 1
18
Wuhan
2025-02-17
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
34
Wuhan
2025-02-15
By invitation
Longboard Pharmaceuticals
Phase 3
324
Beijing, Guangzhou, Shenzhen Shi, Wuhan, Shanghai Shi
2025-02-12
Recruiting
Research on the Effect of Noise Cancelling Headphones in Reducing Postoperative Pain
NCT06918470Noise Cancelling Headphones, Postoperative Pain
Maternal and Child Health Hospital of Hubei Province
Not applicable
300
Wuhan
2025-02-12
Active, closed
AbbVie
Phase 3
468
Beijing, Guangzhou, Shijiazhuang, Wuhan, Suzhou, Xi'an, Taiyuan, Tianjin
2025-02-10
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1
20
Wuhan
2025-02-10
Active, closed
Tongji Hospital
Not applicable
130
Wuhan
2025-02-10
Active, closed
Novartis Pharmaceuticals
Phase 3
180
Hefei, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Wuxi, Changchun, Beijing
2025-02-07
Active, closed
Cardioneuroablation for Variant Angina
NCT06992830Variant Angina
Zhibing Lu
Not applicable
16
Wuhan
2025-02-07
By invitation
Ding Ma
Observational
20
Wuhan
2025-02-01
Recruiting
Therapy on Perioperative Anxiety and Pain in Patients
NCT06970431Music Therapy, Anxiety, Health Education
Maternal and Child Health Hospital of Hubei Province
Not applicable
300
Wuhan
2025-02-01
Not yet open
Wan-Guang Zhang
Phase 1
21
Wuhan
2025-02-01
Recruiting
Chronic Airway Disease and Multimorbidity Cohort
NCT06798077Chronic Obstructive Pulmonary Disease (COPD), Asthma, Bronchiectasis
China-Japan Friendship Hospital
Observational
2,000
Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Shenyang, Xi'an, Shanghai
2025-02-01
Recruiting
Nutritional Intervention for Biliary Atresia
NCT06764082Nutrition Disorder, Infant, Biliary Atresia
Tongji Hospital
Not applicable
120
Wuhan
2025-02-01
By invitation
Huazhong University of Science and Technology
Not applicable
1,438
Wuhan
2025-02-01
Recruiting
Tongji Hospital
Not applicable
166
Wuhan
2025-02-01
Not yet open
Fuling Zhou
Phase 1/2
42
Zhengzhou, Wuhan, Xianning
2025-02
Active, closed
Novartis Pharmaceuticals
Phase 3
588
Fuzhou, Guangzhou, Wuhan, Changsha, Changchun, Shenyang, Xian, Chengdu
2025-01-31
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Hefei, Beijing, Guangzhou, Wuhan, Harbin, Changsha, Chengdu, Hangzhou
2025-01-29
Recruiting
A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma
NCT06791681Relapsed/ Refractory Multiple Myeloma
Chunrui Li
Early Phase 1
24
Wuhan
2025-01-27
Recruiting
Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease
NCT07872423Anti IL-6R, Castleman's Disease, Multicentric
Beijing VDJBio Co., LTD.
Phase 3
45
Beijing, Xiamen, Wuhan, Nanjing, Nanchang, Taiyuan, Chengdu, Hangzhou
2025-01-27
Recruiting
Risk Prediction Model for Iodinated Contrast Medium Extravasation
NCT06859242Extravasation of Contrast Media
Zhang Wenyan
Observational
1,000
Wuhan
2025-01-25
Active, closed
Akeso
Phase 1/2
110
Wuhan
2025-01-21
By invitation
Establishment of a Predictive Model for Post-dural Puncture Headache
NCT06800859Spinal and Epidural Anaesthesia-Induced Headache During Pregnancy
DrugBlood
Yilin Zhao
Observational
480
Wuhan
2025-01-20
Recruiting
Tongji Hospital
Not applicable
20
Wuhan
2025-01-20
Recruiting
AbbVie
Phase 2
150
Beijing, Fuzhou, Nanning, Harbin, Zhengzhou, Wuhan, Nanchang, Xi'an
2025-01-20
Recruiting
Sinovac Life Sciences Co., Ltd.
Phase 2
400
Wuhan
2025-01-20
Active, closed
Sinocare
Not applicable
160
Beijing, Chongqing, Shunde, Wuhan, Jinan, Shanghai
2025-01-17
Recruiting
Tongji Hospital
Observational
20
Wuhan
2025-01-16
Recruiting
Hong Chen
Early Phase 1
6
Wuhan
2025-01-16
Active, closed
Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD
NCT06724809NMOSD, Neuromyelitis Optica Spectrum Disorders
DrugEculizumab
Alexion Pharmaceuticals, Inc.
Phase 3
21
Beijing, Dongguan, Jinan, Shanghai, Taiyuan, Wenzhou, Wuhan
2025-01-16
Recruiting
Grit Biotechnology
Phase 1
30
Wuhan
2025-01-14
Active, closed
Pfizer
Phase 3
1,035
Hefei, Beijing, Fuzhou, Foshan, Guangzhou, Nanning, Harbin, Wuhan
2025-01-06
Recruiting
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
NCT06764238Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)
DrugsBlinatumomab·Methotrexate·Vincristine·Venetoclax
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3
1,800
Hefei, Fuzhou, Guangzhou, Nanning, Guiyang, Wuhan, Changsha, Nanjing
2025-01-03
Not yet open
Zhongnan Hospital
Not applicable
60
Wuhan
2025-01-01
Recruiting
Longitudinal AI-Assisted Management of Indeterminate Pulmonary Nodules
NCT07895277Pulmonary Nodules, Lung Neoplasms
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not applicable
6,000
Wuhan
2025-01-01
Recruiting
XiaoJing Zou,MD
Not applicable
26
Wuhan
2025-01-01
Recruiting
Probiotics in Advanced Urothelial Carcinoma
NCT06904573Advanced Urothelial Carcinoma, Probiotics, Immunotherapy
DrugsEnfortumab Vedotin·Disitamab Vedotin·Toripalimab·Nab-paclitaxel
Sun Yat-sen University
Phase 2
222
Guangzhou, Wuhan
2025-01-01
Recruiting
Management of Pancreatic Cystic Lesions Using Artificial Intelligence Based on EUS and Multimodal Data
NCT07463872Pancreatic Cystic Lesion, Mucinous Cystadenoma of Pancreas, Intraductal Papillary Mucinous Neoplasm of Pancreas, Pseudocyst Pancreas
Huazhong University of Science and Technology
Observational
500
Wuhan
2025-01-01
Recruiting
Clinical Evaluation of New Biomarkers for Ischemic Cerebrovascular Disease
NCT06890702Ischemic Stroke, Ischemic Cerebrovascular Disease
Tongji Hospital
Observational
7,000
Wuhan
2025-01-01
Not yet open
Suzhou Maximum Bio-tech Co., Ltd.
Phase 1
12
Wuhan
2025-01-01
Active, closed
Zhongnan Hospital
Not applicable
30
Wuhan
2025-01-01
By invitation
Radiomics-Based Non-Invasive MRI Differentiation of Uterine Sarcomas and Fibroids
NCT07129005Uterine Fibroid, Uterine Sarcoma, Diagnose Disease, AI (Artificial Intelligence)
Tongji Hospital
Observational
520
Wuhan
2025-01-01
Not yet open
Wuhan Optics Valley Vcanbiopharma Co., Ltd.
Phase 1/2
149
Wuhan
2025-01
Not yet open
Validation of Joint-AI in Diagnosing Pancreatic Solid Lesions
NCT06753318Pancreatic Cancer, Pancreatitis, Pancreatic Neuroendocine Neoplasms (pNETs), Autoimmune Pancreatitis
Huazhong University of Science and Technology
Not applicable
716
Wuhan
2025-01
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2
80
Wuhan
2024-12-31
Active, closed
Amgen
Phase 2
61
Beijing, Fuzhou, Zhengzhou, Wuhan, Changsha, Changchun, Jinan, Shanghai
2024-12-26
Recruiting
China-Japan Friendship Hospital
Observational
500
Beijing, Wuhan
2024-12-25
Recruiting
Ruijin Hospital
Early Phase 1
66
Wuhan, Nanjing, Shanghai
2024-12-23
Active, closed
Xinhong Wu, PhD
Phase 2
40
Wuhan
2024-12-20
Recruiting
Zhongnan Hospital
Early Phase 1
15
Wuhan
2024-12-19
Active, closed
Healthgen Biotechnology Corp.
Phase 2
336
Beijing, Wuhan, Hohhot
2024-12-19
Recruiting
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
NCT06656494Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)
DrugsICP-248·Azacitidine
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
266
Hefei, Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Nanchang
2024-12-18
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
138
Guangzhou, Nanning, Wuhan, Changsha, Nanjing, Jinan, Linyi, Chengdu
2024-12-17
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
300
Wuhan
2024-12-17
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
1,000
Wuhan
2024-12-17
Recruiting
Nanjing IASO Biotechnology Co., Ltd.
Observational
1,500
Beijing, Tianjin, Wuhan, Zhengzhou
2024-12-15
Active, closed
AbbVie
Phase 2
185
Beijing, Langfang, Harbin, Wuhan, Hangzhou
2024-12-13
Recruiting
Chongqing Precision Biotech Co., Ltd
Phase 1
48
Wuhan
2024-12-12
Recruiting
Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCN
NCT06690827AML (Acute Myeloid Leukemia), BPDCN (Blastic Plasmacytoid Dendritic Cell Neoplasm)
Chongqing Precision Biotech Co., Ltd
Phase 1
30
Wuhan
2024-12-12
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
142
Xiamen, Wuhan, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Linyi
2024-12-12
Recruiting
Peking University People's Hospital
Observational
163
Beijing, Wuhan, Zhengzhou
2024-12-09
Recruiting
Grit Biotechnology
Phase 1
12
Wuhan
2024-12-06
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
116
Chongqing, Guangzhou, Shenzhen, Liuzhou, Wuhan, Changsha, Wuxi, Changchun
2024-12-04
By invitation
Huazhong University of Science and Technology
Observational
240
Wuhan
2024-12-04
Recruiting
Huazhong University of Science and Technology
Phase 4
60
Wuhan
2024-12-04
Recruiting
luxia Kong
Not applicable
100
Wuhan
2024-12-03
Recruiting
Angioplasty With Shockwave IVL Catheter System in Femoropopliteal Lesions
NCT06713850Peripheral Artery Disease (PAD), Chronic Limb Threatening Ischemia
Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology
Observational
130
Wuhan
2024-12-01
Recruiting
Hubei Cancer Hospital
Phase 2
50
Wuhan
2024-11-28
Recruiting
Lee's Pharmaceutical Limited
Phase 3
440
Hefei, Beijing, Wuhan, Changsha, Hangzhou
2024-11-28
Recruiting
Hubei Cancer Hospital
Phase 2
51
Wuhan
2024-11-28
Recruiting
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
NCT06668103Non-Small Cell Lung Cancer With EGFR Mutation
DrugsABSK043·Furmonertinib
Abbisko Therapeutics Co, Ltd
Phase 2
54
Hefei, Harbin, Wuhan, Changchun, Shanghai
2024-11-25
Recruiting
Junwei Yan
Observational
1,000
Wuhan
2024-11-22
Recruiting
Efficacy and Safety of Peginterferon in ET and PV.
NCT06734637Essential Thrombocythemia, Polycythemia Vera
DrugPeginterferon α-2b
Zhenya Hong
Not applicable
40
Wuhan
2024-11-20
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not applicable
15
Wuhan
2024-11-20
Recruiting
Tongji Hospital
Observational
50
Wuhan
2024-11-18
Active, closed
Pfizer
Phase 3
636
Beijing, Chongqing, Guangzhou, Jingzhou, Wuhan, Changsha, Suzhou, Wuxi
2024-11-15
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
42
Bozhou, Chuzhou, Hefei, Ma’anshan, Wuhu, Harbin, Zhengzhou, Wuhan
2024-11-14
Recruiting
Tongji Hospital
Observational
50
Wuhan
2024-11-13
Active, closed
AbbVie
Observational
110
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Dalian, Xi'an, Qingdao
2024-11-13
Active, closed
Longboard Pharmaceuticals
Phase 3
367
Beijing, Guangzhou, Shenzhen Shi, Wuhan, Shanghai Shi
2024-11-11
Recruiting
Ranok Therapeutics (Hangzhou) Co., Ltd.
Phase 1/2
152
Nanning, Zhengzhou, Wuhan, Hangzhou, Shanghai
2024-11-08
Recruiting
Tongji Hospital
Phase 1
29
Wuhan
2024-11-04
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2
80
Wuhan
2024-11-04
Recruiting
Effect of Different Surgical Approaches of Granulomatous Mastitis
NCT06712524Breast-conserving Plastic Surgery, Granulomatous Mastitis
Hubei Cancer Hospital
Not applicable
240
Wuhan
2024-11-01
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
86
Wuhan
2024-11-01
Not yet open
Abnormal Glucose Tolerance in Allogeneic Hematopoietic Stem Cell Transplantation
NCT06704542ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Diabetes Mellitus, Impaired Fasting Glucose
Ruijin Hospital
Observational
1,000
Zhengzhou, Wuhan, Shanghai, Hangzhou, Tianjin
2024-11
Not yet open
Guangdong Association of Clinical Trials
Not applicable
342
Dongguan, Foshan, Guangzhou, Shenzhen, Nanning, Guiyang, Wuhan, Changsha
2024-11
Not yet open
Identification Of High-risk Coronary Plaques By Multimodal Intravascular Imaging
NCT06681155Coronary Arterial Disease (CAD), Acute Coronary Syndromes
Chinese PLA General Hospital
Observational
500
Shenzhen, Wuhan, Changchun, Xi'an, Ürümqi, Hangzhou, Beijing
2024-11
Not yet open
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
350
Wuhan
2024-10-31
Recruiting
RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies
NCT06732492NK T-Cell Lymphoma, CART Therapy, CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies
DrugRD13
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1
10
Wuhan
2024-10-31
Recruiting
Akeso
Phase 3
510
Wuhan, Chengdu
2024-10-30
By invitation
Intelligent Accelerated MRI for Pediatric Abdominal Pain
NCT07164651Pediatric Abdominal Pain
Yaqi Shen，MD，PhD
Observational
150
Wuhan
2024-10-30
Recruiting
Huilan Zhang
Phase 2/3
124
Wuhan
2024-10-25
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
100
Wuhan
2024-10-25
Recruiting
Santen Pharmaceutical Co., Ltd.
Phase 3
180
Hefei, Beijing, Shantou, Guiyang, Zhengzhou, Ha’erbin, Wuhan, Xiangyang
2024-10-22
Active, closed
Pfizer
Phase 3
609
Wuhu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Guilin, Wuhan
2024-10-21
Not yet open
Renmin Hospital of Wuhan University
Phase 2
172
Wuhan
2024-10-20
Recruiting
BeOne Medicines
Phase 1
153
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan
2024-10-18
Recruiting
argenx
Phase 3
69
Beijing, Bengbu, Chengde, Hohhot, Huai'an, Huizhou, Tianjin, Wuhan
2024-10-18
Recruiting
Tongji Hospital
Observational
5,000
Wuhan
2024-10-14
Recruiting
Boehringer Ingelheim
Phase 2
588
Beijing, Changsha, Hangzhou, Hefei, Nanchang, Nanjing, Shanghai, Wuhan
2024-10-11
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
53
Wuhan
2024-10-09
By invitation
CNCMT：a Multi-center, Prospective, Single-arm Study
NCT06714084Locally Advanced Cervical Cancer, PD1, CTLA4
Hubei Cancer Hospital
Not applicable
20
Wuhan
2024-10-08
Recruiting
Thumbtack Needle in the Treatment of NVP
NCT06566274Nausea and Vomiting in Pregnancy (NVP)
Dongmei Huang
Not applicable
320
Jingzhou, Nanzhang Chengguanzhen, Qianjiang, Shiyan, Suizhou, Wuhan, Xiangyang, Xiaogan
2024-10-01
Recruiting
Tongji Hospital
Observational
400
Wuhan
2024-10-01
Recruiting
Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors
NCT06843629Ovarian Cancer, Lung Adenocarcinoma, Pancreatic Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
100
Wuhan
2024-10-01
Recruiting
Opioid-Free Combined Anesthesia With Spontaneous Breathing for VATS
NCT06367218Video-assisted Thoracoscopic Lung Surgery；Anesthesia
Tongji Hospital
Not applicable
480
Wuhan
2024-10-01
Recruiting
Efficacy and Safety of Calculus Bovis Sativus (CBS) for Adult Encephalitis (CBSinEncephalitis)
NCT06584045Encephalitis, Encephalitis, Viral, Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody, Autoimmune Encephalitis
DrugCalculus bovis sativus
Tongji Hospital
Not applicable
250
Wuhan
2024-09-30
Active, closed
Pulsed-Field Ablation With/Without Electrogram Mapping
NCT07541989Non-paroxysmal Atrial Fibrillation
Xu Liu
Not applicable
300
Wuhan, Changshu, Xuzhou, Jinan, Wenling, Yuhuan, Shanghai
2024-09-30
Active, closed
AbbVie
Phase 1
31
Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanchang, Shenyang, Hangzhou
2024-09-30
Recruiting
Bactiseal Catheter Safety Registry Study
NCT06276543Hydrocephalus
Integra LifeSciences Corporation
Observational
200
Beijing, Guangzhou, Harbin, Wuhan, Shanghai, Chengdu
2024-09-29
Active, closed
Longboard Pharmaceuticals
Phase 3
108
Beijing, Guangzhou, Shenzhen Shi, Wuhan, Shanghai Shi
2024-09-25
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
100
Beijing, Chongqing, Guangzhou, Wuhan, Xi’an, Chengdu, Hangzhou, Huzhou
2024-09-21
Not yet open
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3
60
Hefei, Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Nanjing, Nanchang
2024-09-20
Recruiting
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Phase 1
33
Beijing, Nanchang, Shanghai, Suzhou, Wuhan, Xuzhou
2024-09-19
Recruiting
Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)
NCT06726421Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic
Sun Yat-sen University
Phase 3
252
Fuzhou, Guangzhou, Wuhan, Changchun, Chengdu, Wenzhou, Beijing, Shanghai
2024-09-18
Active, closed
Amgen
Phase 1
49
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changchun, Chengdu, Beijing
2024-09-17
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
60
Wuhan
2024-09-15
Recruiting
Hui Xu
Phase 4
373
Wuhan
2024-09-15
Recruiting
Chongqing Claruvis Pharmaceutical Co., Ltd.
Phase 2/3
254
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Kaifeng, Wuhan, Huai'an
2024-09-14
Recruiting
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
NCT06288360Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative, Neoadjuvant Chemoimmunotherapy
DrugsPaclitaxel-albumin·Camrelizumab·Cisplatin
Tongji Hospital
Phase 2
40
Hefei, Beijing, Chongqing, Lanzhou, Nanning, Wuhan, Changsha, Shenyang
2024-09-12
Active, closed
Takeda
Phase 3
2,099
Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Wuhan, Zhenjiang, Shanghai
2024-09-04
Recruiting
Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer
NCT06289751Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Radical Hysterectomy, Extrafascial Hysterectomy
DrugsPaclitaxel-albumin·Cadonilimab·Cisplatin
Tongji Hospital
Phase 2
50
Wuhan, Jinan
2024-09-03
By invitation
Screening and Prospective Cohort Study of Risk Factors for Enhanced Recovery After Spinal Fusion Surgery in Advanced Age Patient
NCT06591442Lumbar Disk Herniation, Lumbar Spinal Stenosis, Lumbar Spondylolisthesis, Cervical Spondylotic Myelopathy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
500
Wuhan
2024-09-03
Not yet open
Shanghai Chest Hospital
Not applicable
134
Wuhan, Nanchang, Shanghai, Ürümqi, Wenzhou
2024-09-01
Recruiting
Tang-Du Hospital
Not applicable
96
Wuhan, Nanjing, Shenyang, Xi'an, Chengdu, Ürümqi, Chongqing, Shanghai
2024-09-01
Recruiting
Real-World Case Registry Study on Obesity
NCT07448090Obesity & Overweight, Obesity (Disorder)
Hubei Hospital of Traditional Chinese Medicine
Observational
10,000
Wuhan
2024-08-31
Recruiting
Bayer
Phase 3
444
Beijing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin, Wuhan, Changsha
2024-08-28
Active, closed
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197Moderate to Severe Crohn's Disease
DrugAZD7798
AstraZeneca
Phase 2
120
Beijing, Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing, Wuhan
2024-08-28
Active, closed
Amgen
Phase 2
32
Beijing, Chongqing, Fuzhou, Guangzhou, Jiangmen, Harbin, Wuhan, Tianjin
2024-08-27
Active, closed
Zenas BioPharma (USA), LLC
Phase 2
93
Beijing, Suzhou, Tianjin, Ürümqi, Wuhan
2024-08-26
Recruiting
iRegene Therapeutics Co., Ltd.
Phase 1
6
Wuhan
2024-08-23
Active, closed
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1/2
20
Shanghai, Wuhan
2024-08-22
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Early Phase 1
6
Wuhan
2024-08-20
Recruiting
Liu Huang
Not applicable
80
Wuhan
2024-08-20
Active, closed
Genmab
Phase 3
379
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2024-08-13
Recruiting
Chengdu Qingshan Likang Pharmaceutical Co., Ltd
Phase 4
400
Hefei, Beijing, Wuhan, Changsha, Chengdu, Chongqing, Ganzhou, Guangdong
2024-08-09
Recruiting
IASO-782 in Autoimmune Hematological Diseases
NCT06534021Autoimmune Thrombocytopenia, Warm Autoimmune Haemolytic Anaemia
DrugIASO-782
Shanghai IASO Biotechnology Co., Ltd
Phase 1
16
Wuhan, Tianjin
2024-08-08
By invitation
Zhongnan Hospital
Phase 1/2
25
Wuhan
2024-08-08
Recruiting
Efficacy and Safety of Calculus Bovis Sativus (CBS) for Ischemic Cerebral Vascular Disease (CBSinICVD)
NCT06474507Ischemic Cerebrovascular Disease, Acute Ischemic Stroke, Cerebral Small Vessel Diseases
DrugCalculus bovis sativus
Tongji Hospital
Not applicable
230
Wuhan
2024-08-08
Recruiting
Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)
NCT06474520Idiopathic Inflammatory Demyelinating Disease, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
DrugCalculus bovis sativus
Tongji Hospital
Not applicable
250
Wuhan
2024-08-08
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1
170
Changsha, Fuzhou, Hangzhou, Kunming, Shanghai, Wuhan
2024-08-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
3,000
Beijing, Chongqing, Guangzhou, Huizhou, Shenzhen, Jingzhou, Wuhan, Changsha
2024-08-05
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
5,500
Guangzhou, Wuhan, Yangzhou, Shenyang, Chengdu, Hangzhou
2024-08-01
Not yet open
Wuhan University
Observational
300
Wuhan
2024-08-01
Recruiting
Predictive Algorithms for Critical Rehabilitation Outcomes
NCT06532994Intensive Care, Mechanical Ventilation, Rehabilitation, Algorithms
Wuhan University
Observational
250
Wuhan
2024-08-01
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
150
Wuhan
2024-08
Not yet open
Clinical Study of 18F-Alfatide Injection PET/CT
NCT06416852Non-Small Cell Lung Cancer NSCLC
DrugFluorodeoxyglucose
Yantai LNC Biotechnology Singapore PTE. LTD.
Phase 3
428
Wuhan
2024-08
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
150
Wuhan
2024-08
Recruiting
Phase 2 Study of WGI-0301 for Advanced HCC
NCT06309485Advanced Hepatocellular Carcinoma (HCC)
Zhejiang Haichang Biotech Co., Ltd.
Phase 2
60
Shanghai, Changsha, Chengdu, Hangzhou, Harbin, Nanchang, Wuhan
2024-07-31
Recruiting
Biomarkers in Autoimmune Disease of Nervous System
NCT06502015Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder, Multiple Sclerosis, Guillain-Barre Syndrome
Tongji Hospital
Observational
50,000
Wuhan
2024-07-31
Recruiting
Xintian Pharmaceutical
Phase 4
234
Chongqing, Xiamen, Guangzhou, Shenzhen, Shunde, Wuhan, Nanjing, Xuzhou
2024-07-30
By invitation
Tongji Hospital
Observational
1,000
Wuhan
2024-07-30
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2
116
Beijing, Nanning, Wuhan, Nanjing, Suzhou, Xuzhou, Nanchang, Shanghai
2024-07-29
Active, closed
Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
NCT06054113B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
DrugBlinatumomab
Amgen
Phase 2
18
Hefei, Chongqing, Guangzhou, Wuhan, Suzhou, Shanghai, Tianjin
2024-07-23
Recruiting
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
NCT06427941Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors
DrugsTislelizumab·Bevacizumab
BeOne Medicines
Phase 1/2
630
Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan
2024-07-23
Recruiting
Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
NCT06484153To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma, To Evaluate Whether Pirfenidone Can Reshape the Tumor Microenvironment in Colorectal Cancer, Combination of Fruquintinib and Anti-PD-1 Antibody Was Reported to Improve Patient Prognosis in Colorectal Cancer
DrugsPirfenidone·Fruquintinib·Pembrolizumab
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
25
Wuhan
2024-07-22
Recruiting
Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease
NCT06499233Pneumonia, Pneumocystis, Autoimmune Inflammatory Rheumatic Disease, Autoimmune Diseases, Connective Tissue Disease
DrugsTMP/SMX·Trimethoprim-sulfamethoxazole
Tongji Hospital
Phase 4
800
Wuhan
2024-07-20
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1
25
Wuhan, Taiyuan
2024-07-20
Recruiting
An In-situ Detection for MicroRNA
NCT06529614Breast Cancer
Tongji Hospital
Observational
100
Wuhan
2024-07-20
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
29
Wuhan, Hubei
2024-07-19
Active, closed
Vor Biopharma
Phase 3
191
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Zunyi, Wuhan
2024-07-17
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
36
Wuhan
2024-07-15
Active, closed
MAXVAX Biotechnology Limited Liability Company
Phase 3
25,000
Shijiazhuang, Zhengzhou, Wuhan, Kunming
2024-07-13
Recruiting
Zheng Liu
Not applicable
15
Wuhan
2024-07-11
Recruiting
A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
NCT06500676KRAS G12D Mutations, Advanced Solid Tumors
DrugCetuximab
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
407
Hefei, Beijing, Guangzhou, Nanning, Haerbin, Zhengzhou, Wuhan, Changsha
2024-07-09
Active, closed
Novartis Pharmaceuticals
Phase 4
318
Hefei, Fuzhou, Guangzhou, Shenzhen, Zunyi, Harbin, Zhengzhou, Wuhan
2024-07-09
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens
NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
DrugIvosidenib
Servier Bio-Innovation LLC
Phase 3
156
Guangzhou, Zhengzhou, Wuhan, Changsha, Shang'ai, Shanghai, Chengdu, Hangzhou
2024-07-09
Active, closed
Novartis Pharmaceuticals
Phase 4
36
Guangzhou, Zhengzhou, Wuhan, Xian, Hangzhou, Beijing, Taian, Tianjin
2024-07-04
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
150
Wuhan
2024-07-02
Not yet open
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not applicable
320
Wuhan
2024-07-01
Recruiting
Tongji Hospital
Not applicable
198
Wuhan
2024-07-01
Recruiting
Tongji Hospital
Observational
100
Wuhan
2024-07-01
Active, closed
Ruijin Hospital
Phase 3
250
Wuhan, Shanghai, Hangzhou
2024-07-01
Not yet open
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 4
702
Wuhan, Qingdao
2024-07-01
Recruiting
Tongji Hospital
Early Phase 1
30
Wuhan
2024-07
Not yet open
Gang Xu
Phase 4
206
Wuhan
2024-07
Recruiting
Tongji Hospital
Early Phase 1
30
Wuhan
2024-07
Recruiting
Differentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath
NCT06518655Pulmonary Nodules, Multiple, Pulmonary Nodules, Solitary, Lung Cancer
ChromX Health
Observational
3,000
Beijing, Foshan, Guangzhou, Wuhan, Shanghai, Chengdu
2024-06-30
Recruiting
Beijing 302 Hospital
Phase 2
140
Lanzhou, Guangzhou, Sanya, Wuhan, Shanghai, Kashgar, Beijing
2024-06-27
Recruiting
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3
264
Anhui Sheng, Beijing, Guangzhou, Zunyi, Shijiazhuang, Zhengzhou, Changsha, Wuhan
2024-06-25
Active, closed
Lyvgen Biopharma Holdings Limited
Phase 2
64
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha
2024-06-21
Recruiting
Huazhong University of Science and Technology
Observational
600
Wuhan
2024-06-21
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
220
Beijing, Fuzhou, Wuhan, Changsha, Shanghai, Chengdu
2024-06-20
Recruiting
Tao Zhang
Phase 1
9
Wuhan
2024-06-19
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2
15
Wuhan
2024-06-19
Recruiting
RemeGen Co., Ltd.
Phase 1/2
24
Guangzhou, Wuhan, Changsha, Nanjing, Chengdu, Tianjin
2024-06-14
Recruiting
Hangzhou Sumgen Biotech Co., Ltd.
Phase 3
360
Beijing, Guangzhou, Luoyang, Zhengzhou, Wuhan, Suzhou, Taiyuan, Xi’an
2024-06-14
Recruiting
Tongji Hospital
Phase 4
100
Wuhan
2024-06-14
Recruiting
Spinal Versus General Anesthesia on Postoperative Pulmonary Complications
NCT06425627Pulmonary Complication, Anesthesia, Hip Fractures
Tongji Hospital
Not applicable
40
Wuhan
2024-06-12
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-06-10
Recruiting
Chujin Cao
Phase 4
120
Wuhan
2024-06-07
Recruiting
Juventas Cell Therapy Ltd.
Observational
200
Beijing, Guangzhou, Zhengzhou, Wuhan, Xuzhou, Jinan, Shanghai, Chengdu
2024-06-05
Recruiting
A Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries
NCT06539689Peripheral Arterial Disease, Stenosis, Dissection
FrontAce Scientific Co., Ltd
Not applicable
240
Beijing, Chongqing, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Nantong, Shanghai
2024-06-04
Recruiting
Tongji Hospital
Phase 2
36
Wuhan
2024-06-04
Recruiting
Qian Chu
Observational
100
Wuhan
2024-06-01
By invitation
Zhen Li
Observational
1,000
Wuhan
2024-06-01
Recruiting
Tongji Hospital
Not applicable
80
Wuhan
2024-06-01
Not yet open
Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer
NCT06361030Pancreatic Cancer, Pancreatic Cancer Non-resectable, Pancreatic Ductal Adenocarcinoma, PDAC
DrugsSurufatinib·Nab-paclitaxel·Gemcitabine
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
40
Wuhan
2024-06-01
Not yet open
Tongji Hospital
Phase 3
360
Wuhan
2024-06-01
Recruiting
Zhiyong Huang
Phase 1
50
Wuhan
2024-06-01
Active, closed
Amgen
Phase 1
120
Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changchun
2024-05-29
Recruiting
Linperlisib Combined With Chidamide in Patients With PTCL
NCT06421948Peripheral T-cell Lymphoma
Yanyan Liu
Phase 1/2
134
Zhengzhou, Wuhan, Changsha, Chengdu, Tianjin, Hangzhou
2024-05-25
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not applicable
50
Wuhan
2024-05-24
Recruiting
A Study of GLB-001 in Patients With Myeloid Malignancies
NCT06378437Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myelodysplastic Syndromes
DrugGLB-001
Hangzhou GluBio Pharmaceutical Co., Ltd.
Phase 1
108
Hefei, Beijing, Chongqing, Shijiazhuang, Zhengzhou, Wuhan, Suzhou, Nanchang
2024-05-24
Recruiting
A Study of GQ1010 in Subjects With Advanced Solid Tumors
NCT06464055Advanced Malignant Solid Tumors
DrugPhase II
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Phase 1/2
260
Beijing, Harbin, Tianjin, Wuhan, Zhengzhou
2024-05-23
Recruiting
Renmin Hospital of Wuhan University
Observational
7,500
Wuhan
2024-05-20
Recruiting
Pelvic Floor Rehabilitation of Female Pelvic Floor Dysfunction
NCT06461234Pelvic Floor Disorders, Pelvic Organ Prolapse
Mingfu Wu
Observational
1,360
Wuhan
2024-05-20
Active, closed
AbbVie
Phase 3
421
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang
2024-05-19
Active, closed
Bristol-Myers Squibb
Phase 4
84
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Nanchang
2024-05-15
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2
36
Guangzhou, Wuhan, Changsha
2024-05-15
By invitation
Yilin Zhao
Phase 4
180
Wuhan
2024-05-10
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
28
Wuhan
2024-05-08
Active, closed
Zhongnan Hospital
Not applicable
110
Wuhan
2024-05-08
Recruiting
Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer
NCT06289062Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Fertility Preservation
DrugsCamrelizumab·Nab-paclitaxel·Cisplatin
Tongji Hospital
Phase 2
40
Guangzhou, Wuhan
2024-05-08
Recruiting
Research on Body Voice AI Recognition System for Children's Health Management
NCT06542120Congenital Heart Disease, Bronchopneumonia, Abdominal Disease
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Observational
30,000
Wuhan, Changsha, Shanghai, Kunming
2024-05-01
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
27
Wuhan
2024-05-01
Recruiting
Xu Yu
Not applicable
120
Wuhan
2024-04-29
Recruiting
DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
NCT06539182Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
DrugBirelentinib
Dizal Pharmaceuticals
Phase 2
155
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Changchun, Dalian
2024-04-29
Recruiting
Tyligand Pharmaceuticals (Suzhou) Limited
Phase 1/2
440
Hefei, Beijing, Guangzhou, Wuhan, Changsha, Nanchang, Linyi, Shanghai
2024-04-29
Recruiting
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 1
24
Wuhan
2024-04-28
Recruiting
Zheng Liu ENT
Observational
150,000
Wuhan
2024-04-27
Recruiting
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
NCT06288373Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy, Neoadjuvant Chemoimmunotherapy
DrugsCamrelizumab·Nab-paclitaxel·Cisplatin
Tongji Hospital
Phase 2/3
440
Hefei, Beijing, Chongqing, Lanzhou, Nanning, Wuhan, Changsha, Shenyang
2024-04-22
Recruiting
Janssen Research & Development, LLC
Phase 1/2
287
Beijing, Cheng Du Shi, Linyi, Shanghai, Wuhan
2024-04-22
Active, closed
Amgen
Phase 3
111
Beijing, Shenzhen, Wuhan, Suzhou, Changchun, Jinan, Chengdu, Shanghai
2024-04-22
Recruiting
Peking Union Medical College Hospital
Observational
3,000
Hefei, Beijing, Nanning, Zhengzhou, Henan, Ningbo, Shanghai, Wuhan
2024-04-19
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
138
Bengbu, Beijing, Chengde, Harbin, Zhengzhou, Wuhan, Zhuzhou, Shenyang
2024-04-17
Recruiting
Harbin Medical University
Not applicable
1,860
Beijin, Zunyi, Daqing, Harbin, Jiamusi, Mudanjiang, Zhengzhou, Wuhan
2024-04-16
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
300
Wuhan
2024-04-15
Recruiting
Hunan University
Not applicable
360
Wuhan, Changsha
2024-04-12
Recruiting
BeOne Medicines
Phase 1
308
Beijing, Fuzhou, Guangzhou, Harbin, Wuhan, Dalian, Shenyang, Jinan
2024-04-12
Active, closed
Janssen Research & Development, LLC
Phase 3
272
Beijing, Cheng Du Shi, Chongqing, Guangzhou, Shenyang, Tianjin, Wenzhou, Wuhan
2024-04-09
Recruiting
Ascentage Pharma Group Inc.
Phase 3
344
Bengbu, Guangzhou, Zhanjiang, Zhengzhou, Wuhan, Changsha, Shanghai, Tianjin
2024-04-07
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Suzhou
2024-04-03
Recruiting
Grit Biotechnology
Phase 2
83
Beijing, Fuzhou, Shenzhen, Guilin, Ha’erbin, Luoyang, Zhengzhou, Wuhan
2024-04-02
Recruiting
Chen Xiaoping
Phase 4
300
Wuhan
2024-04-01
Recruiting
The Safety, Tolerability, and Efficacy of KD01 in Gynecologic Malignancies
NCT06552598Cervical Cancer, Gynecologic Malignancies, Endometrial Cancer
DrugKD01
Tongji Hospital
Phase 1
97
Wuhan
2024-04-01
Recruiting
Chen Xiaoping
Phase 4
300
Wuhan
2024-04-01
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
458
Wuhan
2024-04-01
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
300
Wuhan
2024-03-30
Recruiting
Bausch & Lomb Incorporated
Not applicable
418
Beijing, Dongcheng, Xiamen, Haikou, Wuhan, Shanghai, Taiyuan, Shenzhen
2024-03-29
Recruiting
Second Affiliated Hospital of Nanchang University
Phase 4
424
Hefei, Heihe, Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2024-03-28
Recruiting
Medtecx Co Ltd.
Not applicable
126
Hefei, Beijing, Wuhan, Nanjing, Nanchang, Xi'an, Shanghai, Tianjin
2024-03-26
Active, closed
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 2
240
Langfang, Xingtai, Zhengzhou, Jingzhou, Wuhan, Jinan, Liaocheng, Changzhi
2024-03-24
Active, closed
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
NCT06380660Solid Tumor, Adult, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer
Acerand Therapeutics (Shanghai) Limited
Phase 1/2
298
Chongqing, Fuzhou, Guangzhou, Anyang, Zhengzhou, Wuhan, Changsha, Jinan
2024-03-22
Recruiting
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1
108
Zhengzhou, Wuhan, Nanchang, Tianjin, Hangzhou
2024-03-21
Recruiting
Sun Yat-sen University
Phase 2
162
Guangzhou, Dongguan, Foshan, Shenzhen, Wuhan
2024-03-19
Recruiting
Anhui Provincial Hospital
Early Phase 1
9
Hefei, Wuhan
2024-03-15
Recruiting
Zhiyong Huang
Observational
60
Wuhan
2024-03-15
Recruiting
Anhui Provincial Hospital
Phase 3
198
Hefei, Beijing, Zhengzhou, Wuhan, Shanghai, Hangzhou
2024-03-15
Recruiting
Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy
NCT06037733Advanced Non-Small Cell Squamous Lung Cancer, Radiotherapy, Immunotherapy
Hubei Cancer Hospital
Not applicable
134
Wuhan
2024-03-13
Recruiting
Shanghai Jiao Tong University School of Medicine
Observational
2,242
Chongqing, Xiamen, Wuwei, Qinzhou, Luoyang, Shangqiu, Xuchang, Wuhan
2024-03-11
Recruiting
Xiaorong Dong
Phase 2
45
Wuhan
2024-03-07
Recruiting
Takeda
Phase 2
268
Chongqing, Xiamen, Guangzhou, Huizhou, Wuhan, Changsha, Changzhou, Suzhou
2024-03-05
Recruiting
Atomized Inhalation ICG for Treatment of Congenital Lung Malformations
NCT06302985Pulmonary Sequestration, Congenital Pulmonary Airway Malformation, Indocyanine Green, Thoracoscopic Surgery
Jiexiong Feng
Not applicable
50
Wuhan
2024-03-01
Active, closed
Tongji Hospital
Observational
2,000
Wuhan
2024-03-01
Recruiting
Sichuan University
Phase 2
114
Chongqing, Guiyang, Wuhan, Chengdu, Nanchong
2024-03-01
Recruiting
Guihua Wang
Not applicable
404
Wuhan
2024-03-01
Active, closed
Anhui Provincial Hospital
Phase 3
198
Hefei, Beijing, Zhengzhou, Wuhan, Shanghai, Hangzhou
2024-03-01
Recruiting
Clinical Study of PEG Bowel Preparation in Appendectomy Patients
NCT07478029Appendicitis, Appendicitis Acute
Huaping Xie
Observational
10
Wuhan
2024-02-23
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
100
Hefei, Beijing, Hunan, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-02-22
Active, closed
Abbisko Therapeutics Co, Ltd
Phase 1
164
Hefei, Fuzhou, Xi'an, Harbin, Zhengzhou, Wuhan, Changsha, Nanchang
2024-02-22
Recruiting
RemeGen Co., Ltd.
Phase 2/3
90
Beijing, Xiamen, Harbin, Zhengzhou, Wuhan, Changsha, Xuzhou, Jinan
2024-02-22
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yangzhou
2024-02-20
Active, closed
Pfizer
Phase 1/2
71
Guangzhou, Wuhan, Xi'an
2024-02-19
Not yet open
Henan Cancer Hospital
Phase 2
48
Zhengzhou, Wuhan
2024-02-10
Recruiting
Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy
NCT06020430Non Small Cell Lung Cancer, Locally Advanced, Radiotherapy, Immunotherapy
Hubei Cancer Hospital
Not applicable
134
Wuhan
2024-02-08
Recruiting
Lingli Dong
Not applicable
24
Wuhan
2024-02-05
Active, closed
Genmab
Phase 3
1,095
Beijing, Xiamen, Guangzhou, Shenzhen, Nanning, Zhengzhou, Wuhan, Changsha
2024-02-05
Recruiting
Analysis of the Incidence and Risk Factors of Chronic Pain After Cesarean Section
NCT06704490Postoperative Pain, Cesarean Section Surgery
Huazhong University of Science and Technology
Observational
600
Wuhan
2024-02-01
Recruiting
Hubei Cancer Hospital
Phase 2
49
Wuhan
2024-02-01
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
121
Chongqing, Fuzhou, Guangzhou, Liuzhou, Luoyang, Zhengzhou, Wuhan, Changsha
2024-01-29
Recruiting
Tongji Hospital
Phase 2
336
Wuhan
2024-01-29
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 1
339
Hefei, Beijing, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2024-01-23
Recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
152
Beijing, Guangzhou, Haerbin, Zhengzhou, Wuhan, Changsha, Jinan, Qingdao
2024-01-23
Recruiting
Tongji Hospital
Observational
250
Wuhan, Beijing, Changchun, Chongqing, Nanjing
2024-01-20
Active, closed
Pfizer
Phase 3
394
Guangzhou, Wuhan, Shenyang, Shanghai, Kunming
2024-01-19
Recruiting
Zhongnan Hospital
Phase 3
154
Zhengzhou, Huanggang, Jingzhou, Shiyan, Wuhan, Xianning, Xiaogan, Yichang
2024-01-18
Recruiting
AstraZeneca
Phase 1/2
334
Beijing, Chengdu, Shanghai, Wuhan
2024-01-18
Recruiting
iRegene Therapeutics Co., Ltd.
Phase 1/2
40
Beijing, Wuhan
2024-01-17
Recruiting
Renmin Hospital of Wuhan University
Observational
450
Wuhan
2024-01-17
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2
15
Wuhan
2024-01-12
Recruiting
Tongji Hospital
Phase 2
82
Wuhan
2024-01-11
Recruiting
Hangzhou GluBio Pharmaceutical Co., Ltd.
Phase 1
110
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Shenyang
2024-01-11
Active, closed
AbbVie
Phase 4
120
Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Wuhan, Qingdao, Chengdu
2024-01-09
Active, closed
Pfizer
Phase 2
333
Wuhan, Changsha, Shanghai
2024-01-09
Recruiting
A Single Center Randomized Controlled Study on the Promotion of Rapid Recovery
NCT06250699Nonfunctional Adrenal Cortex Adenoma, Primary Aldosteronism, Cushing Syndrome
Zhe Meng
Not applicable
200
Wuhan
2024-01-03
Recruiting
Shanghai Xinzhi BioMed Co., Ltd.
Phase 2/3
55
Beijing, Guangzhou, Guiyang, Wuhan, Changsha, Suzhou, Xi’an, Chengde
2024-01-03
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
38
Wuhan
2024-01-01
Recruiting
Tongji Hospital
Observational
50,000
Wuhan
2024-01-01
Recruiting
The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
NCT06236022Dilated Cardiomyopathy, Kaposi's Sarcoma-Associated Herpesvirus Infection
DrugSirolimus
Tongji Hospital
Phase 4
276
Wuhan
2024-01-01
By invitation
Tongji Hospital
Not applicable
212
Wuhan
2024-01-01
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,310
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Wuhan, Changsha
2023-12-31
Recruiting
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease
NCT06189495Systemic Sclerosis Associated Interstitial Lung Disease, Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD), Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
DrugGenSci048
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 2
30
Beijing, Wuhan, Jinan, Chengdu
2023-12-30
Recruiting
Tongji Hospital
Phase 2
36
Wuhan
2023-12-30
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Early Phase 1
13
Wuhan
2023-12-27
Recruiting
Teligene US
Phase 2
66
Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Nanchang, Jinan
2023-12-27
Recruiting
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1/2
110
Beijing, Hangzhou, Jinan, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an
2023-12-26
Recruiting
Wuhan High Myopia Study
NCT06162234High Myopia
Renmin Hospital of Wuhan University
Observational
1,000
Wuhan
2023-12-25
Recruiting
Bivision Pharmaceuticals, Inc.
Phase 1/2
90
Hefei, Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Suzhou, Wuxi
2023-12-22
Active, closed
Bristol-Myers Squibb
Phase 3
190
Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-12-21
Recruiting
Ascentage Pharma Group Inc.
Phase 3
400
Hefei, Beijing, Fuzhou, Foshan, Guangzhou, Nanning, Zhengzhou, Wuhan
2023-12-20
Recruiting
Tavotek Biotherapeutics
Phase 1
50
Chongqing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Jinan
2023-12-20
Active, closed
AbbVie
Phase 3
614
Beijing, Guangzhou, Wuhan, Xi'an, Jinan, Shanghai, Chengdu, Tianjin
2023-12-19
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
324
Bengbu, Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Dalian
2023-12-19
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,314
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Wuhan, Changsha, Nanjing
2023-12-18
Recruiting
Bio-Thera Solutions
Phase 2/3
526
Wuhan
2023-12-13
Recruiting
Beijing Hospital
Phase 2
296
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Hohhot, Shenyang
2023-12-02
Active, closed
Tongji Hospital
Observational
100
Wuhan
2023-12-01
Recruiting
Hubei Cancer Hospital
Not applicable
98
Wuhan
2023-12-01
Not yet open
Wen-hong Zhang
Observational
5,000
Hefei, Fuzhou, Wuhan, Nanjing, Xuzhou, Jinan, Taiyuan, Xi’an
2023-12-01
Active, closed
Feng Gao
Observational
144
Wuhan
2023-12-01
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
45
Wuhan
2023-12-01
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
80
Wuhan
2023-12
Recruiting
Ruijin Hospital
Phase 2
30
Beijing, Guangzhou, Henan, Shanghai, Wuhan
2023-11-30
Recruiting
Liu Huang
Phase 2
25
Wuhan
2023-11-28
Recruiting
Renmin Hospital of Wuhan University
Observational
4,000
Wuhan
2023-11-28
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
100
Wuhan
2023-11-20
Active, closed
AbbVie
Phase 3
289
Chongqing, Xiamen, Guangzhou, Wuhan, Changsha, Changzhou, Nanjing, Wuxi
2023-11-15
Active, closed
Pfizer
Phase 3
1,571
Beijing, Fuzhou, Guangzhou, Guiyang, Shijiazhuang, Nanyang, Wuhan, Changsha
2023-11-08
Recruiting
Mao Jianhua
Phase 3
140
Wuhan, Nanjing, Kunming, Hangzhou, Ningbo, Wenzhou, Beijing, Shanghai
2023-11-01
Recruiting
Allist Pharmaceuticals, Inc.
Phase 2
88
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-10-27
Active, closed
Novartis Pharmaceuticals
Phase 3
612
Hefei, Chongqing, Guangzhou, Shenzhen, Wuhan, Baotou, Nanjing, Nanchang
2023-10-27
Recruiting
OriCell Therapeutics Co., Ltd.
Phase 1/2
83
Hangzhou, Beijing, Nanjing, Shanghai, Wuhan
2023-10-26
Active, closed
Bristol-Myers Squibb
Phase 3
402
Hefei, Beijing, Chongqing, Xiamen, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2023-10-24
Active, closed
Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
NCT06165380Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapies
Li Zhang
Phase 2
43
Wuhan
2023-10-23
Active, closed
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
NCT05952037Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
DrugsSonrotoclax·Zanubrutinib
BeOne Medicines
Phase 2
114
Xiamen, Guangzhou, Zhengzhou, Wuhan, Yancheng, Shenyang, Qingdao, Shanghai
2023-10-23
Not yet open
Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC
NCT05993858Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
DrugCetuximab
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
33
Wuhan
2023-10-20
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
54
Wuhan
2023-10-20
Recruiting
Abbisko Therapeutics Co, Ltd
Phase 2
82
Shanghai, Chengdu, Ha’erbin, Wuhan
2023-10-17
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1/2
63
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yongzhou, Shenzhen, Xi’an
2023-10-17
Recruiting
AbbVie
Phase 3
1,500
Beijing, Chongqing, Guangzhou, Shenzhen, Wuhan, Nanchang, Changchun, Xi'an
2023-10-11
Rows per page Showing 501–1000 of 1343
Previous 1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/wuhan?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,343 of those studies with a site in Wuhan.

How many clinical trials are recruiting in Wuhan?

805 of the 1,343 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 223 have not yet opened recruitment, 279 are active but closed to new participants, and 36 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.